GENERAL ASPECTS FOR STATISTICAL ANALYSIS 6.1. GENERAL METHODS The methods outlined below apply to both Stage 1 and Stage 2 unless otherwise specified.  All statistical analyses and summaries will be produced using SAS® version 9.3 (or higher).  All enrolled patients (i.e., patients who signed the ICF) will be accounted fo r in this study. All relevant patient data will be included in patient data listings.  Patient data listings will be sorted by treatment group (i.e., SL-701/ GM-CSF/Imiquimod (Regimen 1); SL-701/poly-ICLC/bevacizumab (Regimen 2) or screen failures), patient number and assessment date (and time) if applicable.  The total number of patients in the ITT/mITT/PPP Populations will be use d as the denominator for percentage calculations for efficacy assessments, and the total number of patients in the ITT Population will be used as the denominator for percentage calculation for safety assessments, unless otherwise stated in the table.  Continuous variables will be summarized using the number of non-missing observations (n), mean, standard deviation (SD), median, minimum and maximum.  Categorical variables will be summarized using the number of non-missing observation (n), frequency counts and percentage s.  Multiple assessments at a given time point (planned, repeat, unscheduled) will not be included in summary tables unless otherwise specified, but will be included in patient data listings. If there are multiple laboratory results at a given visit, then the latest non-missing val ue will be used in summary tables.  Shift tables will be produced for selected assessments and will contain counts and percentages of patients in each cross-classification level of baseline versus post-baseline assessment. Onl y patients with a non-missing value for both baseline and post-baseline assessments, at a given visit, will be included in these tables.  Data for unscheduled assessments will be included when calculating changes from baseline values, selecting the latest results for shift analyses, and for the summarization of normal/abnormal values. Summaries of observed values and change from baseline data will be performed by nominal visits (ie, scheduled visits). The process for assigning unscheduled visit data to nominal visits is summarized in Section 6.4 of this SAP. DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 23 of 63 6.2.